

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
28 October 2004 (28.10.2004)

PCT

(10) International Publication Number
WO 2004/092183 A2

- (51) International Patent Classification⁷: **C07D 501/06, 501/44**
- (21) International Application Number: **PCT/EP2004/003988**
- (22) International Filing Date: 15 April 2004 (15.04.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
A 586/2003 16 April 2003 (16.04.2003) AT
A 585/2003 16 April 2003 (16.04.2003) AT
A 584/2003 16 April 2003 (16.04.2003) AT
- (71) Applicant (for all designated States except US): **SANDOZ AG [CH/CH]**; Lichtstrasse 35, CH-4056 Basel (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **LUDESCHER, Johannes [AT/AT]**; Kleinsöll 101, A-6252 Breitenbach (AT). **STURM, Hubert [AT/AT]**; Edith-Stein-Weg 2, A-6020 Innsbruck (AT). **WOLF, Siegfried [AT/AT]**; Judenwiese 4a, A-6230 Brixlegg (AT).
- (74) Agent: **GRUBB, Phillip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CEFEPIME PROCESSES

WO 2004/092183 A2




(57) Abstract: This invention provides processes for preparing cefepime, including crystalline intermediates.

Cefepime processes

5

The present invention relates to the preparation of 1-[[(6R,7R)-7-[(2Z)-(2-amino-4-thiazoly)methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-pyrrolidinium dihydrochloride hydrate (cefepime dihydrochloride monohydrate), hereafter "cefepime". Cefepime is a valuable 4th generation injectable 10 cephalosporin with antibacterial properties, see e.g. The Merck Index Thirteenth Edition, Item 1935, and is used e.g. in the form of a dihydrochloride hydrate of formula I



15 Presently known methods for preparing cefepime are far from straightforward. For example, it is known that the 7-acyl side chain as the difficultly obtainable 2-(2-aminothiazol-4-yl)-2-methoxyimino-acetic acid hydrochloride must be used for the production of cefepime, in order to obtain an active ingredient which is pure in respect of the by-products known as anti-isomer and Δ-2 isomer.


20

The present applicants have sought to overcome the problems of hitherto known processes.


In one aspect, therefore, this invention provides a process comprising reaction of a β-lactam intermediate of formula II A or II B

25

- 2 -



II A




II B

5 wherein

 R_1 is trialkylsilyl, R is H or trialkylsilyl n is 0 - 2 and X is chloride, bromide or iodide,

10 with a reactive derivative of the compound of formula III




III

- 3 -

wherein Y is halogen or a leaving group,
to form a compound of formula IV or V

5

IV




x -

wherein T is trialkylsilyl, the silyl protecting groups - if present - are removed,
if necessary the intermediate step of formula V

10

V



. m HX

is isolated wherein m is 0 or 1,

the compound of formula IV, or the compound of formula V, is reacted with thiourea and

15 subsequently the compound of formula I is isolated.

Examples of trialkylsilyl protecting groups are trimethylsilyl and triethylsilyl.

When Y represents halogen, Y may denote chloride, bromide or iodide, preferably chloride or

20 bromide. Leaving group is understood in the context of this invention to denote a group

which is removed by reaction with e.g. thiourea, e.g. alkyl or aryl sulfonyl, e.g. C₁ – C₄ alkyl sulfonyl.

Unless otherwise stated, alkyl means C₁ – C₈ alkyl, e.g. C₁ – C₄ alkyl, e.g. methyl, ethyl,

- 5 propyl or butyl and may be straight or branched chain.

Unless otherwise stated, the compounds of formula II A and II B are referred to as compounds of formula II.

- 10 It will be appreciated that the compounds of formula II or V may exist in mixtures. Thus the compound of formula II A may exist in a mixture having a proportion where n is 1, and a proportion where n is 2. The compound of formula II B may exist in a mixture comprising mono- and di-silylated forms.

- 15 The compounds of formula II may be used in free base form, as a mono-addition salt or as a di-addition salt with a hydrohalic acid such as hydrochloric acid, hydrobromic acid or hydriodic acid. The addition salts may additionally be present in solvated form, e.g. as a hydrate.

- 20 If the silylation variant is chosen, the intermediate of formula II B is obtained by known methods, using a silylation agent such as N,O-bis-(trimethylsilyl)-acetamide (BSA), N,O-bis-(trimethylsilyl)-trifluoroacetamide (BSTFA), N-methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA) or for example hexamethyldisilazane (HMDS), in a solvent that is inert towards silylation agents, for example a nitrile, such as acetonitrile, an ether, for 25 example tetrahydrofuran, or a chlorinated hydrocarbon, for example dichloromethane.

Subsequently, the silylated derivative of formula II B is acylated with a reactive derivative of formula III, the reactive derivative being an acid chloride, acid bromide or active ester, for example a S-mercaptopbenzothiazoyl ester, optionally in the presence of an auxiliary base

- 30 such as a tertiary alkylamine.

The compound of formula IV is subsequently desilylated with the assistance of a protic reagent, for example water or an alcohol, and then the compound of formula V is reacted with thiourea in an aqueous or organic-aqueous medium. Cefepime is subsequently crystallised, if necessary after separating the organic solvent, and where appropriate after removing any salt
5 that is present, for example after treatment using anion exchangers by known methods after adding hydrochloric acid from an aqueous acetonnic solution.

An alternative is to work in an aqueous or aqueous-organic system, for example in a one-phase system consisting of water and a water-miscible solvent, for example a ketone, such as acetone, a nitrile, such as acetonitrile, or an ether, such as tetrahydrofuran, or in a two-phase system, for example in a combination of an ester of acetic acid, for example ethyl acetate, a chlorinated hydrocarbon, for example dichloromethane, or for example an aromatic hydrocarbon, for example toluene, whereby the compound of formula IIA is optionally released from its respective mono- or di-addition salt form with the assistance of a base, for
10 example caustic soda solution or caustic potash solution, a sodium or potassium hydrogen carbonate or alkali carbonate, or by known methods using an ion exchanger, and subsequently the compounds of formula II are acylated with a reactive derivative of formula III. After the acylation reaction has taken place, thiourea is added, and after optionally separating the organic solvent, the title compound is isolated by known methods by adding acetone from an
15 aqueous/acetonnic solution.
20

Suitable ion exchangers include ion exchange resins comprising e.g. LA2 which is available commercially from the Rohm and Haas company.

25 If desired, it is possible to isolate the compound of formula V, at this stage as an addition salt with a hydrohalic acid, for example as the hydrochloride, or isolate as free base. Here, the reaction sequence preferably starts with an acid addition salt of the compound of formula II, via the silylation route. By adding small amounts of protic solvent, for example water or an alcohol, to the compound of formula IV, the silyl groups are removed, and the halide present
30 in the system enables direct crystallisation of the compound of formula V to take place. The preferred mono-addition salt is the monohydrochloride in crystalline form. In order to produce

this, the compound of formula II A is preferably used as the mono- or di-hydrochloride addition salt, and the preferred solvents for crystallisation are acetonitrile in combination with isopropanol.

- 5 To isolate the compound of formula V as free base in crystalline form, the above procedure may be used with addition of a suitable base to the solution or suspension of the acid addition salt of the compound of formula V. Alternatively, the acid addition salt of the compound of formula V may be isolated and subsequently converted to the corresponding free base by addition of a suitable base. Suitable bases include for example trialkylamines, e.g.
- 10 triethylamine for example in an alcoholic solvent such as methanol.


In US 4,266,049, a 7-acyl-3-acetoxymethyl-cephalosporinate is converted with the assistance of an iodotrialkylsilane into the corresponding persilylated 3-iodomethyl compound and this then undergoes nucleophilic substitution in the 3'-position. This technology can only be applied to the production of cefepime - starting with cefotaxime - to an uneconomical extent, since N-methylpyrrolidine as a strong base can greatly induce the formation of the by-products Δ-2 und 7-epi (Walker *et al*, J.Org Chem. 1988, pages 983-991).

The present applicants found that working with N-methylpyrrolidine - trialkylsilane adducts
20 iodotrimethylsilane and N-methylpyrrolidine as described in the above literature led to unsatisfactory results when using cefotaxime as the starting material.

In another aspect therefore, this invention provides a synthesis route from cefotaxime (see Merck Index, 12th Edition, item 1983) in accordance with the following scheme:

25 cefotaxime in acid or sodium salt form ->

- 7 -



The choice of silylation agent is crucial to the smooth conversion of cefotaxime into a reactive, silylated derivative of formula VII, whereby R signifies hydrogen or a trialkylsilyl group. Suitable silylation agents are iodotrimethylsilane in the presence of a non-nucleophilic

5 base, N,O-bis-(trimethylsilyl)-trifluoroacetamide (BSTFA), (for example US 4,336,253); N-methyl-N-trimethyl-silyltrifluoroacetamide (MSTFA) (for example EP 74 268); 1,1,1,3,3,3-hexamethyldisilazane (HMDS) or a combination of all the said silylation agents. The compound of formula VIII is then produced in known manner with iodotrimethylsilane.

10 According to the above synthesis method, the silylated compound of formula VIII is treated simultaneously or substantially simultaneously with a protic solvent and N-methylpyrrolidone, whereby in a first step the compound of formula IX is produced and this is then rapidly reacted with N-methylpyrrolidine. The reaction accordingly illustrates a desilylation reaction, followed by salt formation on the carboxylic acid and nucleophilic substitution. This principle
15 simultaneously minimises the instability of the highly reactive iodomethyl grouping by an *in situ* reaction with N-methylpyrrolidine, and through the (desilylation) salt formation on the carboxylic acid, by-product $\Delta 2$ formation is drastically reduced.


Suitable protic solvents are, in particular, alcohols, for example C₁-C₄-alcohols, preferred
20 alcohols being ethanol and isopropanol. The amount of protic solvent is not critical, however the applicants have obtained favourable results when the reaction proceeds in a homogeneous solution or suspension, and through insolubility, the compound of formula IX is extracted from the possible further reaction in salt form or in free acid form.

25 In a preferred embodiment, the compound of formula VIII is mixed with a mixture of N-methylpyrrolidine and alcohol, preferably isopropanol. In this way, not only does the above-described reaction sequence take place, but the title compound is obtained as an addition salt with hydroiodic acid. This can be isolated from the reaction mixture directly. The iodide is removed from the product simply by treatment in an aqueous or aqueous-organic solution, for
30 example in a mixture of dichloromethane/water, with a commercial anion exchanger, for example with Amberlite LA-2 (from Rohm & Haas), and by adding hydrochloric acid the

active ingredient can subsequently be crystallised as the dihydrochloride hydrate according to known methods, for example from an aqueous/acetonic solution.

In one embodiment, the isolated hydroiodide may be converted into the corresponding free
 5 amphoteric ion (betaine) of formula XI, for example by treatment with a trialkylamine, e.g. trimethylamine, triethylamine or tributylamine, in an organic solvent such as dichloromethane, and after isolation by known methods, this may be converted into the title compound cefepime dihydrochloride hydrate.


10



A further aspect of this invention provides a novel process for the production of cefepime which is notable for the simplicity of the choice of solvent and the accessibility and facile
 15 handling of the 7-acyl side chain, and which at the same time leads to an active ingredient with high purity in respect of the above-mentioned by-products.

The process comprises the reaction of a pyrrolidinium-1-[(7-amino-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-yl)methyl]-halide, an acid addition salt thereof or its free base of
 20 formula IIA with (Z)-(2-aminothiazol-4-yl)methoxyimino-acetic acid-2-mercaptopbenzothiazoleester of formula XII

25



- in an acetonic or aqueous/acetonic solution, optionally in the presence of a base, wherein
cefepime dihydrochloride monohydrate is precipitated in crystalline form directly from the
5 reaction mixture by adding HCl.

The process is straightforward. Neither extraction steps nor more complex purification operations are necessary. The solvent regeneration is an especially simple procedure, in that only one solvent is used both for the acylation reaction and for the crystallisation step.

- 10 The intermediate compound of formula II A may be present as mono-addition salt or di-addition salt or a mixture thereof. In addition, the intermediate of formula II A may be present in the form of a solvate, for example a hydrate. The usual addition salts are represented by the mono- and dihydrochloride or the hydriodide.
- 15 Depending on the salt form, the corresponding acid addition salt is released for the reaction with the acylation agent with the assistance of the necessary amount of a base, preferably a trialkylamine. Accordingly, a mono-addition salt is released with approximately one molar equivalent of base, and a di-addition salt is correspondingly released with approximately two. However, it is also possible to react the corresponding acid addition salt with (Z)-(2-
- 20 aminothiazol-4-yl)methoxyimino-acetic acid-2-mercapto-benzothiazoleester without adding a base.

- If the intermediate of formula II A is used as the mono- or dihydrochloride, the active ingredient cefepime is obtained as the pure dihydrochloride. If the intermediate is used as the
25 hydriodide, the recrystallised product is practically and substantially free from traces of iodide.

Alternatively, foreign ions can be removed from the reaction solutions by known methods, for example with the assistance of an anion exchanger.

Suitable trialkylamines are C₁-C₈-trialkylamines, for example triethylamine or tributylamine. The presence of water in the acylation reaction in principle also allows the use of inorganic bases, for example sodium or potassium hydroxide or an alkali hydrogen carbonate or alkali carbonate, e.g. sodium or potassium hydrogen carbonate or carbonate.

5

The reaction is preferably carried out in the presence of water: the amount of water is not critical; there must be balanced solubility of the cephalosporin intermediate of formula IIA and of the active ester of formula XII. The water/acetone ratio may be between 1:10 to 10:1, and preferably a water/acetone ratio of 1:1 to 1:5 is used for the acylation reaction. After the 10 acylation reaction, in order to crystallise cefipime dihydrochloride, hydrochloric acid is added, preferably aqueous concentrated hydrochloric acid, and a pH value of less than 3, preferably less than 1, is set. By adding acetone, the crystallisation of cefepime dihydrochloride is then completed. Preferred water/acetone ratios in the crystallisation step are ratios of 1:1 to 1:20, especially ratios of 1:3 to 1:10.

15

The processes of this invention may be carried out between -40°C and room temperature, for example between -35°C and 15°C, preferably between -25°C and about 1°C.

Following is a description by way of example only of processes of this invention.

20

Figure 1 is an X-ray spectrum of the compound of formula V as hydrochloride; Figure 2 is an X-ray spectrum of the compound of formula V as base (betaein).

The following abbreviations are used:

25 NMP⁺ to denote N-methylpyrrolidinium
NMP-ACA to denote an intermediate compound of Formula IIA

Example 1

Preparation of starting material 4-chloro-2-methoxyimino-3-oxo-butyryl chloride

30

- 12 -

A solution of 0.488 g of 4-chloro-2-methoxyiminobutyric acid in 8.0 ml of acetonitrile is mixed at -20°C with 0.353 g of chloromethylene iminium chloride (Vilsmeier reagent) and stirred for 1 hour at -20°C.

5 Example 2a

Preparation of 1-[(6R,7R)-7-[(2Z)-(4-chloro-2-methoxyimino-3-oxo-butyryl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-pyrrolidinium hydrochloride

10 1.55 g of N,O-bistrimethylsilylacetamide are added dropwise at room temperature to a suspension of 0.835 g of NMP-ACA.2HCl in 10.5 ml of acetonitrile. After stirring for 25 mins at room temperature, the solution obtained is cooled to -35°C. At this temperature, a solution of 4-chloro-2-methoxyimino-3-oxo-butyryl chloride in acetonitrile (for preparation see example 1a), which has been cooled to -20°C, is added. After stirring for 1 hour in a
15 cooling bath at -35°C, 2 ml of isopropanol are added dropwise. The resulting suspension is heated to 0°C and stirred for 1 hour in an ice bath. The suspension is then filtered. The filter cake is washed with acetonitrile. After drying in a vacuum at room temperature, 1.42 g of product is obtained as a white crystalline powder.

20 ¹H-NMR spectrum (DMSO-d6, δ in ppm)

1,957 – 1,690 (m, 2H, pyrrolidinyl-H); 2,943 (s, 3 H, N-CH3); 3,371 – 3,701 (m, 5 H, pyrrolidinyl-H, S-CH2); 3,866 (1 H, J = 10,0 Hz, S-CH2); 4,060 (s, 3 H, OCH3); 4,329 and 4,597(ABq, 2 H, J = 13,7 Hz, .-CH2-N); 4,846 (s, 2 H, CH2Cl); 5,322 (d, 1 H, 5,1 Hz, H6); 5,884 (dd, 1H, J = 8,4 Hz, J = 5,1 Hz, H7); 9,555 (d, 1H, NH)

25

Example 2b

Preparation of 1-[(6R,7R)-7-[(2Z)-(4-chloro-2-methoxyimino-3-oxo-butyryl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-pyrrolidinium hydrochloride

1.63 g of trimethylsilylchloride are added dropwise at room temperature to a suspension of 5.00 g of NMP-ACA.HCl in 190 ml of acetonitrile. After stirring for 10 mins at room temperature 8.5 ml acetonitrile are added and then the suspension is cooled to 0°C. At this temperature 7.74 g N,O-bistrimethylsilyacetamide are added dropwise. After stirring for 20

5 mins the resulting solution is cooled to – 20°C. At this temperatur a solution of 4-chloro-2-methoxyimino-3-oxo-butyryl chloride in acetonitrile (prepared from 3.03 g 4-chloro-2-methoxyimino-3-oxo-butyryl acid, 2.16 g of chloromethylene iminium chloride (Vilsmeier reagent) and 45 ml acetonitrile; preparation see example 1a), which has been cooled to –20°C, is added. After stirring for 1 hour in a cooling bath at –25°C the cold reaction mixture is

10 added within 20 minutes to a mixture of 148 ml acetonitrile and 14 ml methanol and by addition of a solution of ethyldiisopropylamine in acetonitrile (10%) the pH is maintained in the range 2.0 – 1.5. The resulting suspension is stirred for 1 hour in an ice bath. The suspension is then filtered. The filter cake is washed with acetonitrile. After drying in a vacuum at room temperature, 7.20 g of product is obtained as a white crystalline powder.

15 The corresponding X-ray spectrum is shown in Figure 1.

Example 2c

Preparation of 1-[(6R,7R)-7-[[[(2Z)-(4-chloro-2-methoxyimino-3-oxo-butyryl]amino]-2-

carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-pyrrolidinium inner

20 salt

10.64 g of (4-chloro-2-methoxyimino-3-oxo-butyryl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-pyrrolidinium hydrochloride (for preparation see above) is suspended in 95 ml cold methanol. To the suspension is added

25 dropwise at 0°C a solution of 8.1g triethylamine in 30 ml methanol. The suspension is stirred for 1 hour in an ice bath. The suspension is then filtered. The filter cake is washed with cold methanol. After drying in a vacuum at room temperature, 7.57 g of product is obtained as a white crystalline powder.

The corresponding X-ray spectrum is shown in Figure 2.

Example 3

Preparation of 1-[(6R,7R)-7-[(2Z)-(2-amino-4-thiazolyl)methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-pyrrolidinium dihydrochloride hydrate (cefepime dihydrochloride monohydrate).

5

0.990 g of 1-[(6R,7R)-7-[(2Z)-(4-chloro-2-methoxyimino-3-oxo-butyryl)amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-pyrrolidinium hydrochloride are added at 4°C to a solution of 0.152 g of thiourea in 5 ml of H₂O. The pH of the suspension is adjusted to pH 6.0 with ion exchanger LA-2 and maintained in the pH range of 5.5 to 6.0 by adding LA-2 dropwise. After stirring for 8.5 hours at 2 to 4°C, the reaction mixture is washed with 10 ml of methylene chloride. After phase separation, the aqueous phase is washed a second time with 10 ml of methylene chloride. The organic phases are combined and then extracted with 3 ml of H₂O. The aqueous phases are combined and mixed with 0.20 g of activated carbon. After stirring for 10 minutes, the carbon suspension is filtered. The carbon cake is washed with 1.5 ml of H₂O. The filtrate and washing water are combined, acidified with 6 m HCl to pH 0.6 and mixed with 50 ml of acetone. After adding seed crystals, stirring is effected for 15 minutes at room temperature, and then a further 50 ml of acetone is added dropwise over the course of 1 hour. The crystal suspension obtained is cooled to 0°C. After stirring for 1 hour in an ice bath, the suspension is filtered and the filter cake is washed with acetone. After drying in a vacuum at room temperature, 0.561 g of the title compound are obtained in the form of a white crystalline powder.

HPLC purity: 99.6 area %

Example 4

25 Preparation of 1-[(6R,7R)-7-[(2Z)-(2-amino-4-thiazolyl)methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-pyrrolidinium dihydrochloride hydrate (cefepime dihydrochloride monohydrate).

1.55 g of N,O-bistrimethylsilylacetamide are added dropwise at 1°C to a suspension of

30 0.835 g of pyrrolidinium-1-[(7-amino-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-

yl)methyl]-dihydrochloride in 10.5 ml of acetonitrile. After stirring for 45 mins in an ice bath, the solution obtained is cooled to -35°C. At this temperature, a solution of 4-chloro-2-methoxyimino-3-oxo-butyryl chloride (for preparation see example 1a), which has been cooled to -20°C, is added. After stirring for 1 hour in a cooling bath at -35°C, 2 ml of H₂O are added dropwise. After stirring for 10 minutes at -35°C, 0.38 g of thiourea are added. The reaction mixture is subsequently heated to 0°C and the pH is adjusted to 6.0 by adding ion exchanger LA-2, and is maintained at this pH. After stirring for 2 hours in an ice bath, the 2-phase reaction mixture obtained is mixed with 2 ml of H₂O. After stirring for a further 16 hours at 0 to 4°C, the pH is acidified to pH 0.6 with 6 m HCl. After adding 50 ml of methylene chloride, the phases are separated. The methylene chloride phase is then extracted with 3 ml of H₂O. The aqueous phases are combined and mixed with 0.10 g of activated carbon. After stirring for 10 minutes, the activated carbon suspension is filtered. The carbon cake is washed with 1 ml of H₂O. The filtrate and washing water are combined and diluted with 30 ml of acetone. After adding seed crystals, stirring is effected for 30 minutes at room temperature. Then, 20 ml of acetone are added dropwise to the resulting crystal suspension over the course of 30 minutes. The suspension is cooled to 0°C. After stirring for 1 hour in an ice bath, the product is isolated and the filter cake is washed with acetone. After drying in a vacuum at room temperature, 0.742 g of the title compound are obtained in the form of a white crystalline powder.

HPLC purity: 99.5 area %

Example 5

Preparation of 1-[(6R,7R)-7-[[[(2Z)-(2-amino-4-thiazolyl)methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-pyrrolidinium dihydrochloride hydrate (cefepime dihydrochloride monohydrate).

1.706 g of pyrrolidinium-1-[(7-amino-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-yl)methyl]-dihydrochloride are added to a mixture of 10 ml of H₂O and 5 ml of methylene chloride, and the pH is adjusted to 6.50 by adding ion exchanger LA-2. The 2-phase mixture is cooled in an ice bath to 1°C. At this temperature, a solution of 4-chloro-2-methoxyimino-3-

oxo-butyryl chloride, produced from 1.464 g of 4-chloro-2-methoxyimino-3-oxo-butyric acid (see example 1a), which has been cooled to ~20°C, is added dropwise over the course of 1 hour, whereby the pH is maintained in the range of 6.0 to 6.5 by adding base LA-2. After stirring for 15 minutes in an ice bath, 0.76 g of thiourea are added and stirring is effected for 5 16 hours at 2-4°C. The pH is maintained in the range of 5.5 to 6.0 with LA-2. The reaction mixture is subsequently diluted with 100 ml of methylene chloride. After phase separation, the aqueous phase is washed with 50 ml of methylene chloride. The methylene chloride phases are combined and then extracted with 3 ml of H₂O. The product-containing aqueous phases are combined and mixed with 0.20 g of activated carbon. After stirring for 10 minutes, the 10 activated carbon suspension is filtered. The carbon cake is washed with 1.5 ml of H₂O. The filtrate and washing water are combined and diluted with 60 ml of acetone. After adding seed crystals, stirring is effected for 30 minutes at room temperature. Then, 40 ml of acetone are added dropwise to the resulting crystal suspension over the course of 30 minutes. The suspension is cooled to 0°C. After stirring for 1 hour in an ice bath, the product is isolated and 15 the filter cake is washed with acetone. After drying in a vacuum at room temperature, 1.236 g of the title compound are obtained in the form of a white crystalline powder.

HPLC purity: 90.0 area %

Example 6

20 Preparation of 1-[(6R,7R)-7-[(2Z)-(2-amino-4-thiazoly)methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-pyrrolidinium hydriodide

25 100.0 g of cefotaxime are suspended in 1.2 l of methylene chloride and heated to reflux temperature. Whilst boiling under reflux, 2.5 ml of hexamethyldisilazane (HMDS) and 0.2 ml of trimethyliodosilane are added. Then, 102 ml of HMDS are added dropwise whilst stirring, and stirring is effected at this temperature for 1 hour, whereby the resulting ammonia is removed by passing nitrogen into the reaction suspension. Then, the clear solution obtained is cooled to 10°C. 70 ml of trimethyliodosilane are added dropwise at this temperature. After 30 stirring for 60 minutes, 10 ml of trimethyliodosilane are added dropwise, and after a further 30 minutes, a further 15 ml of trimethyliodosilane are added. After stirring for 165 minutes at

10°C, the reaction solution is stirred over the course of 2 minutes into a solution of 350 ml of N-methylpyrrolidine in 9 l of isopropanol, which has a temperature of 18°C. The resulting suspension is stirred for 1 hour at room temperature. Then, it is filtered through a glass sintering filter and the filter cake is washed with 500 ml of isopropanol. After drying in a vacuum at room temperature, 97.7 g of the title compound are obtained in the form of a yellow coloured powder.

Example 7

Preparation of 1-[(6R,7R)-7-[(2Z)-(2-amino-4-thiazolyl)methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-pyrrolidinium dihydrochloride hydrate.

4.00 g of 1-[(6R,7R)-7-[(2Z)-(2-amino-4-thiazolyl)methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-pyrrolidinium hydriodide are dissolved at room temperature in a mixture of 10 ml of H₂O and 30 ml of methylene chloride. The pH of the mixture is adjusted to 7.3 through the dropwise addition of ion exchanger LA-2. After stirring for 15 minutes, the phases are separated. The aqueous phase is adjusted to pH 2.5 with conc. hydrochloric acid and stirred for 15 minutes. Then, the precipitate formed is separated by filtration. The clear filtrate is acidified to pH 1.0 with conc. hydrochloric acid and mixed with 1.6 g of activated carbon. After stirring for 10 minutes, the activated carbon is removed by filtration and the carbon cake is washed with 5 ml of H₂O. The filtrate and washing water are combined, acidified to pH 0.5 with conc. hydrochloric acid and diluted with 50 ml of acetone. Seed crystals are added, and the resulting crystal suspension is stirred for ca. 20 minutes at room temperature. Subsequently, a further 50 ml of acetone is added dropwise over the course of 30 minutes. When the acetone addition is complete, the crystal suspension is cooled to 0°C. After stirring for 1 hour in an ice bath, the suspension is filtered and the filter cake is washed with acetone. After drying in a vacuum at room temperature, 0.85g of the title compound are obtained in the form of a white crystalline powder. Yield: 36.8%.

30 HPLC purity: > 99 area %

Example 8

Preparation of 1-[(6R,7R)-7-[(2Z)-(2-amino-4-thiazolyl)methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-pyrrolidinium

5 dihydrochloride hydrate

44.3 g of pyrrolidinium-1-[(7-amino-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-iodide monohydrate (NMP-ACA) are suspended in a mixture of 200 ml of H₂O and 400 ml of acetone. 38.5 g of (Z)-(2-aminothiazol-4-yl)methoxy-iminoacetic acid-2-

10 mercaptobenzothiazoleester are added to the suspension. At a temperature of ca. 15°, a mixture of 13.9 ml of triethylamine and 14 ml of acetone is slowly added dropwise to the suspension over the course of 3 hours. The resulting cloudy solution is stirred for a total of 6.5 hours at 20°C.

15 33 ml of 37% HCl are subsequently added to the reaction mixture, and then ca. 300 ml of acetone are added whilst stirring. The mixture is seeded with seed crystals, and within ca. 90 minutes a suspension is produced. Subsequently, within 90 minutes, 1700 ml of acetone are added dropwise whilst stirring gently. The suspension is stirred for a further one hour at room temperature, and then the title compound is isolated through a suction filter, and the product is washed with 250 ml of acetone/H₂O mixture (90/10) and with a total of 500 ml of acetone in two portions. The product is subsequently dried for ca. 18 hours at room

20 temperature in a vacuum drying chamber.

Yield 51.8 g

purity: HPLC: 98.8 area percent

25 Example 9

Recrystallisation of 1-[(6R,7R)-7-[(2Z)-(2-amino-4-thiazolyl)methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-pyrrolidinium dihydrochloride hydrate

50.0 g of cefepime dihydrochloride hydrate are dissolved in 200 ml of H₂O. 22 ml of 6 n HCl are added and then the solution is mixed with 5 g of activated carbon. The suspension is stirred for 10 minutes at room temperature and then filtered through a suction filter. The filter layer is then washed with 50 ml of H₂O, and the combined filtrates are mixed with 600 ml of
5 acetone until turbidity occurs. The resulting suspension is stirred for 15 minutes and then a further 1400 ml of acetone are added over the course of one hour whilst stirring gently. The suspension is stirred for another one hour at room temperature, and the product is subsequently isolated through a suction filter. The product is washed with a total of 500 ml of acetone and dried for ca. 18 hours at room temperature in a vacuum drying chamber.

10

Yield 45.01 g

purity HPLC: 99.7 area percent

15

X-ray diffraction measurements for Examples 2b and 2c


Equipment used:

20 X-Ray Powder Diffractometer D-8 (AXS-BRUKER)
theta-theta-goniometer, sample changer
target: Copper, K α 1+K α 2 λ = 1.5406 Å
parallel beam optics (receiving soller-slit: 0.07 mm)
Scintillation counter, standard sample holders

Data collection parameters: 40kV, 40 mA, 2-40° θ/2θ, 0.01 steps, 2 seconds



Claims

1. A process for producing a compound of formula I



5

wherein a compound of formula II A or II B



10

wherein


R_1 is a trialkylsilyl group,

R is hydrogen or a trialkylsilyl group,


n is 0 - 2 and

- 5 X signifies chloride, bromide or iodide

is reacted with a reactive derivative of formula III




- 10 wherein Y signifies halogen or a leaving group, to form a compound of formula IV or V



wherein T is trialkylsilyl, the silyl protecting groups, if present, are removed , or the

- 15 compound of formula IV as the acid addition salt of formula V is isolated wherein m is 0 or 1
and the compound of formula IV



or the compound of formula V is cyclised with thiourea, and subsequently the compound of formula I is isolated.

5

2. A process as claimed in claim 1, wherein the compounds of formula II are produced from their respective mono- or di- hydrogen halide adducts.

10 3. A process as claimed in claim 1 or 2, wherein pyrrolidinium-1-[(7-amino-2-carboxy-8-oxo-
5-thia-1-azabicyclo[4.2.0]oct-2-en-yl)methyl]-iodide monohydrate is used.

15 4. A process as claimed in claim 1 or 2, wherein pyrrolidinium-1-[(7-amino-2-carboxy-8-oxo-
5-thia-1-azabicyclo[4.2.0]oct-2-en-yl)methyl]-chloride or pyrrolidinium-1-[(7-amino-2-
carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-yl)methyl]-dihydrochloride is used,
optionally in solvated form.

15 5. A compound of formula V, wherein Y and X are Cl.


20 6. A compound as claimed in claim 5 in crystalline form wherein the compound of formula V
is in free base or acid addition salt form.

7. A compound as claimed in claim 6 having an X-ray powder diffraction pattern
substantially as that shown in Figure 1 or Figure 2.

8. A process according to claim 1, characterised in that 4-chloro-2-methoxyimino-3-oxo-butryyl chloride is used as the reactive derivative of formula III.


9. A process as claimed in any of claims 1 to 5 or 8, wherein prior to precipitation or
5 crystallisation of the compound of formula I, any bromide or iodide ions that may be present
are removed by ion exchange.

10. A process for producing the compound of formula I




10

characterised in that a compound of formula VIII




15

is desilylated in a protic solvent, and subsequently reacted with N-methylpyrrolidine to form a compound of formula X, and this is then converted into the compound of formula I



- 5 11. A process as claimed in claim 10, wherein the protic solvent is a C₁-C₄-alcohol.
12. A process according to claim 10 or 11, wherein conversion of the compound of formula VIII is effected using a basic ion exchanger.
- 10 13. A process as claimed in claim 10, 11 or 12, wherein conversion of the compound of formula X into the compound of formula I is effected through the free betaine of formula XI in isolated form




15 .

14. A process for producing the compound of formula I

characterised in that a compound of formula IIA, in unsolvated or solvated form, is reacted optionally after addition of a base, with a compound of formula XII

XII



5

in acetone or aqueous acetone, and the compound of formula I precipitated in crystalline form from the reaction mixture by adding HCl.

- 10 15. A process as claimed in claim 14, wherein pyrrolidinium-1-[(7-amino-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-yl)methyl]-iodide monohydrate is used.
 - 16. A process as claimed in claim 14, wherein pyrrolidinium-1-[(7-amino-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-yl)methyl]-chloride is used, optionally in solvated form.
- 15
- 17. A process as claimed in claim 14, wherein pyrrolidinium-1-[(7-amino-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-yl)methyl]-dihydrochloride is used, optionally in solvated form.
- 20 18. A process as claimed in any one of claims 14 to 17, wherein a C₁-C₈-trialkylamine, KOH or NaOH, or an alkali hydrogen carbonate or potassium carbonate, is used as the base.

^{1/2}

G-33166 A

FIGURE 1





FIGURE 2^{2/2}

G-33166A



2Theta scale (degrees, CuK-alpha)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
28 October 2004 (28.10.2004)

PCT

(10) International Publication Number
WO 2004/092183 A3

- (51) International Patent Classification⁷: C07D 501/06, 501/44
- (21) International Application Number: PCT/EP2004/003988
- (22) International Filing Date: 15 April 2004 (15.04.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
A 586/2003 16 April 2003 (16.04.2003) AT
A 585/2003 16 April 2003 (16.04.2003) AT
A 584/2003 16 April 2003 (16.04.2003) AT
- (71) Applicant (for all designated States except US): SANDOZ AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LUDESCHER, Johannes [AT/AT]; Kleinsöll 101, A-6252 Breitenbach (AT). STURM, Hubert [AT/AT]; Edith-Stein-Weg 2, A-6020 Innsbruck (AT). WOLF, Siegfried [AT/AT]; Judenwiese 4a, A-6230 Brixlegg (AT).
- (74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
9 December 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESSES FOR THE PREPARATIONS OF CEFEPIME

WO 2004/092183 A3



(57) Abstract: This invention provides processes for preparing cefepime, including crystalline intermediates of Formula (V).

INTERNATIONAL SEARCH REPORT

Inte
al Application No
PCT/...2004/003988

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D501/06 C07D501/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 531 981 A (SQUIBB BRISTOL MYERS CO) 17 March 1993 (1993-03-17) example 31 -----	1-9
X	US 6 384 215 B1 (DESHPANDE PANDURANG BALWANT ET AL) 7 May 2002 (2002-05-07) column 2, lines 19-24 columns 4-5 -----	1-9
X	US 2002/156272 A1 (TOTSCHNIG KLAUS ET AL) 24 October 2002 (2002-10-24) inv. 2 page 1, paragraph 5 - paragraph 12 paragraph '0019! paragraph '0019! page 5, paragraph 46-51 -----	1-4, 8, 9
Y	----- -/-	10-13

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the International search

21 September 2004

Date of mailing of the International search report

14.10.2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Grassi, D

INTERNATIONAL SEARCH REPORT

Inventor Application No
PCT/EP2004/003988

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 137 440 A (HOECHST AG) 17 April 1985 (1985-04-17) pages 6-8; claim 1; examples 2-4,10-12,20,21,25,27,44,46,50,53 -----	10-13
X	DATABASE CASREACT XP002297198 Database accession no. 140:111151	14-18
Y	RX(1) & GONG, PING; ZHAO, YANFANG; FENG, RUNLIANG; ZHANG, ZHANTAO; HONGGUO YAOWU HUAXUE ZAZHI, vol. 12, no. 6, 2002, pages 350-351,362, -----	14-18
Y	US 5 574 154 A (ABU-NASRIEH OMAR) 12 November 1996 (1996-11-12) column 3, lines 36-40; figure 1 -----	14-18
X	WALKER D G: "NEW CEPHALOSPORIN ACYLATING AGENTS DERIVED FROM SYN-2-(2-AMINOTHIAZOL-4-YL)-2-METHOXYIMINO ACETIC ACID. APPLICATION TO THE SYNTHESIS OF CEFEPIME SULFATE" TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 31, no. 45, 1990, pages 6481-6484, XP002035970 ISSN: 0040-4039 page 6483 -----	14-18
A	US 4 489 072 A (IMAIZUMI HIROYUKI ET AL) 18 December 1984 (1984-12-18) columns 15-16 -----	1-9

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/003988

Box II Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of Item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-4(part), 5-9

Process for the preparation of Cefepime Dihydrochloride Monohydrate starting from compound IIA and the intermediates according to claims 5-9.

2. claims: 1-4(part)

Process for the preparation of Cefepime Dihydrochloride Monohydrate starting from compound IIB.

3. claims: 10-13

Process for the preparation of Cefepime Dihydrochloride Monohydrate via intermediate VIII.

4. claims: 14-18

Process for the preparation of Cefepime Dihydrochloride Monohydrate applying the reagent XII.

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/EP2004/003988

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0531981	A	17-03-1993		AT 209209 T AU 655838 B2 AU 2284492 A BG 61189 B1 CA 2077836 A1 CN 1070398 A ,B CN 1158333 A ,B CZ 9202780 A3 CZ 9600719 A3 DE 69232216 D1 DE 69232216 T2 DK 531981 T3 EG 20184 A EP 0531981 A1 ES 2165351 T3 FI 924031 A FI 20011921 A HU 62901 A2 IL 103109 A JP 3434840 B2 JP 5194532 A KR 178280 B1 MX 9205147 A1 NO 923495 A NZ 244295 A OA 9764 A PL 295873 A1 PT 531981 T RO 109651 B1 SK 33698 A3 SK 278092 A3 RU 2042681 C1 US 5594129 A ZA 9206866 A	15-12-2001 12-01-1995 11-03-1993 28-02-1997 11-03-1993 31-03-1993 03-09-1997 17-03-1993 11-06-1997 03-01-2002 27-06-2002 21-05-2002 30-09-1997 17-03-1993 16-03-2002 11-03-1993 01-10-2001 28-06-1993 13-07-1997 11-08-2003 03-08-1993 20-03-1999 01-03-1993 11-03-1993 28-08-1995 30-11-1993 04-05-1993 31-05-2002 28-04-1995 12-09-2000 12-09-2000 27-08-1995 14-01-1997 09-03-1993
US 6384215	B1	07-05-2002		NONE	
US 2002156272	A1	24-10-2002		AT 411598 B AU 3967000 A WO 0063214 A1 EP 1169324 A1 US 2002128469 A1 AT 76399 A AT 408225 B AT 1522000 A AT 80099 A	25-03-2004 02-11-2000 26-10-2000 09-01-2002 12-09-2002 15-08-2003 25-09-2001 15-02-2001 15-04-2004
EP 0137440	A	17-04-1985		DE 3409431 A1 AU 3388384 A DK 479684 A EP 0137440 A2 ES 8603497 A1 FI 843933 A GR 80574 A1 HU 37152 A2 HU 190878 B JP 60097983 A MA 20250 A1	18-04-1985 18-04-1985 09-04-1985 17-04-1985 16-04-1986 09-04-1985 01-02-1985 28-11-1985 28-11-1986 31-05-1985 01-07-1985

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/EP2004/003988